Online inquiry

IVTScrip™ mRNA-Anti-ERBB2, MM-302(Cap 1, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ12030MR)

This product GTTS-WQ12030MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets ERBB2 gene. The antibody can be applied in Breast Cancer research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001005862.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2064
UniProt ID P04626
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ERBB2, MM-302(Cap 1, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ12030MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12635MR IVTScrip™ mRNA-Anti-RSPO3, OMP-131R10(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA OMP-131R10
GTTS-WQ6391MR IVTScrip™ mRNA-Anti-Factor IX substitute, CSL654(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CSL654
GTTS-WQ8114MR IVTScrip™ mRNA-Anti-TNFRSF10B, HGS-ETR2(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA HGS-ETR2
GTTS-WQ2976MR IVTScrip™ mRNA-Anti-IL33, ANB020(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ANB020
GTTS-WQ6042MR IVTScrip™ mRNA-Anti-IL6, CNTO 136(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA CNTO 136
GTTS-WQ1750MR IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ADCT-301
GTTS-WQ3512MR IVTScrip™ mRNA-Anti-APP, BAN-2401(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BAN-2401
GTTS-WQ10146MR IVTScrip™ mRNA-Anti-CGRP, LBR-101(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA LBR-101
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW